Pharmaceutical

Image

Global Bronchial Carcinoid Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Oct 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Bronchial Carcinoid Market, By Types (Central Bronchial Carcinoids, Peripheral Bronchial Carcinoids, Others), Treatment (Surgery, Radiation, Chemotherapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Bronchial Carcinoid Market

Bronchial Carcinoid Market Analysis and Size

The global bronchial carcinoid market is expected to witness significant growth during the forecast period. Carcinoid tumor is a rare type of malignant disorder that accumulates for less than 1% of all malignant disorders. About 2 to 4 out of 10 carcinoid tumors are found in the lungs. The cause of lung carcinoid tumors is still unknown. Growing cases of carcinoid tumors, mucoepidermoid carcinoma and family history with lung disorders drives the bronchial carcinoid market. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global bronchial carcinoid market  in the forecast period 2022-2029. The global bronchial carcinoid market  is tend to have a healthy CAGR in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Bronchial Carcinoid Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Types (Central Bronchial Carcinoids, Peripheral Bronchial Carcinoids, Others), Treatment (Surgery, Radiation, Chemotherapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC. (U.S.), Pfizer Inc (U.S.), Mylan N.V. (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany), NATCO Pharma Limited (India), Shilpa Therapeutics Private Ltd. (India)

Market Opportunities

  • Increase in Geriatric Population
  • Higher Indulgence of   Advanced Therapies

Market Definition

Bronchial carcinoid is uncommon, rare disorder that affects 1 to 2% of all lung cancers in adults. It is a slow growing neuroendocrine tumors and low-grade malignant neoplasms rising from bronchial mucosa. Central bronchial carcinoids are common compared to the peripheral and produces symptoms including bronchial obstruction such as cough, localized wheeze, non-resolving recurrent pneumonitis, chest pain, and fever. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.

Global Bronchial Carcinoid Market Dynamics

Drivers

  • Increase in Lung Cancer

According to the GLOBOCAN 2020 estimates by the International Agency for Research on Cancer, about 19.3 million new cases of cancer recorded in 2020 and around 11.4% of them were lung cancer. Lung cancer was the primary cause of death with about 18% or 1.8 million global deaths in 2020. Thus this increasing lung cancer result in the origin of bronchial carcinoid and in return this boost the market growth.

  • Rising Demand for Oral Drugs

Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global bronchial carcinoid market as most products are available in capsule and tablet form and it is a very feasible route of administration.

Opportunities

  • Increase in Geriatric Population

The elderly population is projected to increase the patient population worldwide, which boots the market in the forecast period. As per the reports of WHO, the global elderly population is anticipated to reach about 2 billion by 2050 from 617 million in 2015. The range of possibility of getting infected with varied types of cancer also rises. This boost the market growth.

  • Higher Indulgence of  Advanced Therapies

The rapid growth of the biopharmaceutical industry and the increasing R&D expenses have resulted in the development of several advanced targeted therapeutics to treat lung cancer. The targeted therapy can efficiently treat cancer cells without altering the body's normal cells. This results in nominal side-effects and removes the chances of reoccurrence and deaths. The rising healthcare expenditure combined with the rising awareness associated with the availability of advanced gene therapies that can cure traditionally non-curable diseases has significantly boosted the growth of the targeted therapy across the globe. This creates more opportunities in the market.

Restraints/Challenges

  • Lack of Skilled Professionals

Lack of trained professionals who are not aware of the appropriate treatment methods for this disease could restrain the growth of the global bronchial carcinoid market over a forecast period.

  • High Cost

The huge expenditure of the treatment methods such as radiation therapy, chemotherapy, medications are hamper the market growth.

This global bronchial carcinoid market  report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global bronchial carcinoid market  contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Bronchial Carcinoid Market Scope

The global bronchial carcinoid market is segmented on the basis of type, treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

  • Central Bronchial Carcinoids
  • Peripheral Bronchial Carcinoids
  • Others

Treatment Type

  • Surgery
  • Radiation Therapy
  • Chemotherapy
  • Others

Route of Administration

  • Oral
  • Parenteral
  • Others

End-Users

  • Hospitals
  • Homecare
  • Speciality Centres
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Bronchial Carcinoid Market Regional Analysis/Insights

The global bronchial carcinoid market  is analysed and market size insights and trends are provided by type, treatment type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global bronchial carcinoid market  report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to presence of advanced technology and high R&D & healthcare expenditure.

Asia-Pacific dominates the market due to growing geriatric population suffering from lung disorder, increased usage of cigarettes & alcohol and presence of generic manufacturers.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Bronchial Carcinoid Market Share Analysis

The global bronchial carcinoid market competitive landscape provides details by competitor. Details include company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global bronchial carcinoid market.

Key players operating in the global bronchial carcinoid market  include:

  • Johnson & Johnson Private Limited (U.S.)
  • Cipla Inc. (U.S.)
  • Abbott (U.S.)
  • AbbVie Inc. (U.S.)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Lupin (India)
  • Hikma Pharmaceuticals PLC (U.K.)
  • Amneal Pharmaceuticals LLC. (U.S.)
  • Pfizer Inc (U.S.)
  • Mylan N.V. (U.S.)
  • Bristol-Myers Squibb Company (U.S.)
  • GSK plc. (U.K.)
  • Bayer AG (Germany)
  • NATCO Pharma Limited (India)
  • Shilpa Therapeutics Private Ltd. (India)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

Factors such as increase in lung cancer and increase in oral drugs are acting as the major drivers for the global bronchial carcinoid market
Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Merck KGaA (Germany), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC. (U.S.), Pfizer Inc (U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland), Bristol-Myers Squibb Company (U.S.), GlaxoSmithKline plc. (U.K.), Bayer AG (Germany).
The market segments in the report are Types, Treatments, Routes of Administration & End-Users.
The locations focused on the report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials